MeSH tree: D12.776.124.790.651.114.580
A clinical trial led by researchers from Hospital Clínic de Barcelona, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) compared the effectiveness ...
Jun 10, 2026
0
11
A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies. ...
Jun 2, 2026
0
5
Researchers from The University of Texas MD Anderson Cancer Center have discovered that some cancer cells express the YAP1 protein only after treatment with chemotherapy, allowing them to survive by becoming more invasive ...
May 6, 2026
0
5
Weill Cornell Medicine investigators made an unexpected finding about how the immune system normally suppresses inappropriate chronic inflammation in the intestine, potentially opening new avenues for therapies against inflammatory ...
Apr 26, 2026
0
21
Researchers at the University of British Columbia Faculty of Medicine have developed a new targeted cancer therapy that can precisely seek out and destroy tumor cells—showing strong results in preclinical studies that bring ...
Apr 23, 2026
0
4
Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral ...
Feb 17, 2026
0
21
A new study offers hope that kidney transplant patients could one day have a monthly treatment instead of multiple pills every day. The new treatment may also reduce side effects and increase the lifespan of the donor organ. ...
Feb 3, 2026
0
11
Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.
Jan 21, 2026
0
54
Brazilian researchers have identified previously unknown forms of a protein linked to breast cancer. The discovery contributes to our understanding of variability in responses to treatment, even with the most advanced therapies.
Jan 20, 2026
0
11
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive ...
Dec 25, 2025
0
86
